目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T27644 | |||
J1037 is a novel Histone Deacetylase 8 (HDAC8) inhibitor . | |||
T28690 | |||
SB379278A is a potent inhibitor of HDAC8(IC50 = 0.5 μM). | |||
T61524 | |||
Tubulin/HDAC-IN-1 is a compound that functions as a dual inhibitor for tubulin and HDAC-IN-1. It achieves this by interacting with tubulin through CH/π interaction and with HDAC8 through hydrogen bond interaction. This compound effectively inhibits tubulin polymerization and selectively targets HDAC8 with an IC50 of 150 nM. Additionally, Tubulin/HDAC-IN-1 demonstrates cytotoxicity against various human cancer cells, induces cell cycle arrest in the G2/M phase, and triggers cell apoptosis. This compound is valuable for studying hematologic and solid tumors, including neuroblastoma and leukemia [1]. | |||
T27524 | |||
H8-A5, a HDAC8 inhibitor, shows antiproliferation activity in MDA-MB-231 cancer cells. | |||
T27648 | |||
J1075 is an histone deacetylase 8 (HDAC8) inhibitor. | |||
T5332 | HDAC | ||
TH34 是一种 HDAC6/8/10 抑制剂,IC50值分别为 4.6、1.9 和 7.7 μM。它显示出比 HDAC1/2/3 高的选择性。 | |||
T71512 | |||
NHNB is a selective inhibitor of histone deacetylases-8 (HDAC8). NHNB provides the most potent CE4 inhibitor reported to date. | |||
T27235 | |||
Ebselen oxide is a dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9. | |||
T78769 | HDAC | ||
HDAC6-IN-17(化合物5b)是一种选择性HDAC6抑制剂,其IC50值针对HDAC6为150 nM,相比于HDAC8(1400 nM)和HDAC4(2300 nM)显示出较高的抑制活性。此化合物对人类癌细胞系展现出显著的细胞毒性,常用于癌症的研究领域。 | |||
T72012 | |||
HDAC-IN-6 is an HDAC inhibitor, targeting HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02317 | HDAC8 Protein, Mouse, Recombinant (His) | Mouse | Baculovirus-Insect Cells | ||
Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein that belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It is expressed at a higher level in the heart, brain, kidney, and pancreas and also in the liver, lung, placenta, prostate, and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3, and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
|
|||||
TMPY-01333 | HDAC8 Protein, Human, Recombinant (GST) | Human | Baculovirus-Insect Cells | ||
Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein that belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It is expressed at a higher level in the heart, brain, kidney, and pancreas and also in the liver, lung, placenta, prostate, and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3, and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
|